Healthcare provider profile · identity verified

Matthew Rausch, DO

Family Practice · LEWISTON, ME · NPI 1386266393

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	285	112
Lisinopril	Lisinopril	204	70
Levothyroxine Sodium	Levothyroxine Sodium	172	55
Losartan Potassium	Losartan Potassium	145	48
Amlodipine Besylate	Amlodipine Besylate	142	55
Rosuvastatin Calcium	Rosuvastatin Calcium	126	42
Trazodone Hcl	Trazodone Hcl	120	41
Omeprazole	Omeprazole	102	44
Sertraline Hcl	Sertraline Hcl	94	36
Hydrochlorothiazide	Hydrochlorothiazide	90	31
Pantoprazole Sodium	Pantoprazole Sodium	88	37
Alprazolam	Alprazolam	85	19
Gabapentin	Gabapentin	81	35
Metoprolol Succinate	Metoprolol Succinate	77	29
Lorazepam	Lorazepam	69	18
Simvastatin	Simvastatin	69	27
Escitalopram Oxalate	Escitalopram Oxalate	63	21
Metformin Hcl	Metformin Hcl	61	25
Bupropion Xl	Bupropion Hcl	59	20
Famotidine	Famotidine	56	22
Tramadol Hcl	Tramadol Hcl	56	19
Tamsulosin Hcl	Tamsulosin Hcl	55	21
Citalopram Hbr	Citalopram Hydrobromide	51	14
Duloxetine Hcl	Duloxetine Hcl	49	16
Albuterol Sulfate Hfa	Albuterol Sulfate	48	28
Metoprolol Tartrate	Metoprolol Tartrate	47	18
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	42	18
Venlafaxine Hcl Er	Venlafaxine Hcl	41	13
Fluoxetine Hcl	Fluoxetine Hcl	38	15
Furosemide	Furosemide	38	19
Metformin Hcl Er	Metformin Hcl	38	11
Oxycodone Hcl	Oxycodone Hcl	37	17
Alendronate Sodium	Alendronate Sodium	35	14
Diazepam	Diazepam	33	suppressed
Glipizide Er	Glipizide	33	12
Hydroxyzine Hcl	Hydroxyzine Hcl	33	suppressed
Ozempic	Semaglutide	33	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	33	12
Buspirone Hcl	Buspirone Hcl	28	suppressed
Chlorthalidone	Chlorthalidone	27	11
Eliquis	Apixaban	27	11
Fluticasone Propionate	Fluticasone Propionate	25	suppressed
Baclofen	Baclofen	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	12
Methylphenidate Hcl	Methylphenidate Hcl	21	suppressed
Potassium Chloride	Potassium Chloride	21	suppressed
Celecoxib	Celecoxib	20	suppressed
Montelukast Sodium	Montelukast Sodium	20	suppressed
Pravastatin Sodium	Pravastatin Sodium	20	suppressed
Prednisone	Prednisone	20	18
Trulicity	Dulaglutide	20	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Finasteride	Finasteride	18	suppressed
Lamotrigine	Lamotrigine	18	suppressed
Amoxicillin	Amoxicillin	17	11
Atenolol	Atenolol	17	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Glipizide	Glipizide	17	suppressed
Solifenacin Succinate	Solifenacin Succinate	17	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Estradiol	Estradiol	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	15	suppressed
Carvedilol	Carvedilol	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	11
Valsartan	Valsartan	14	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	11	11
Allopurinol	Allopurinol	11	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error